Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate
To evaluate peripheral blood expression of genes regulated by nuclear factor-kappaB (NF-kappaB), a key mediator of tumor necrosis factor-alpha (TNF-alpha) signaling, in patients with rheumatoid arthritis (RA) before and during treatment with anti-TNF-alpha or methotrexate (MTX). We analyzed associat...
Uloženo v:
| Vydáno v: | Journal of rheumatology Ročník 34; číslo 9; s. 1817 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Canada
01.09.2007
|
| Témata: | |
| ISSN: | 0315-162X |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To evaluate peripheral blood expression of genes regulated by nuclear factor-kappaB (NF-kappaB), a key mediator of tumor necrosis factor-alpha (TNF-alpha) signaling, in patients with rheumatoid arthritis (RA) before and during treatment with anti-TNF-alpha or methotrexate (MTX). We analyzed association of gene expression with disease activity, rheumatoid factor (RF), age, sex, disease duration, treatment modality, and clinical response.
Sixty patients consented for RNA analysis at baseline and after 2 and 6 weeks of treatment. Disease activity was quantified using Disease Activity Score (DAS28) and C-reactive protein (CRP). Expression of 67 TNF-alpha-responsive, NF-kappaB-regulated genes was measured using Affymetrix arrays and RT-PCR.
Expression of 34 genes was associated with DAS28-CRP, notably S100A12/calgranulin C, IL7R, and aquaporin 3. No association was observed with age, sex, RF, or disease duration. Expression of 16 genes changed in a manner that differed significantly between treatment groups. Eleven were reduced in anti-TNF-alpha-treated patients relative to MTX, while 5 were increased. The majority of these observations were confirmed using RT-PCR. Gene expression was not associated significantly with change in disease activity.
NF-kappaB-dependent gene expression in peripheral leukocytes is highly correlated with RA activity as measured by DAS28-CRP. Expression of many genes responds differentially to anti-TNF-alpha versus MTX, suggesting fundamentally different effects on the NF-kappaB pathway. This peripheral blood expression signature provides candidate markers that could lead to development of a simple, minimally invasive pharmacodynamic assay for RA treatments directed at the NF-kappaB pathway. Combination of gene expression data with clinical scores and serum markers may provide more sensitive and predictive measures of RA disease activity. |
|---|---|
| AbstractList | To evaluate peripheral blood expression of genes regulated by nuclear factor-kappaB (NF-kappaB), a key mediator of tumor necrosis factor-alpha (TNF-alpha) signaling, in patients with rheumatoid arthritis (RA) before and during treatment with anti-TNF-alpha or methotrexate (MTX). We analyzed association of gene expression with disease activity, rheumatoid factor (RF), age, sex, disease duration, treatment modality, and clinical response.OBJECTIVETo evaluate peripheral blood expression of genes regulated by nuclear factor-kappaB (NF-kappaB), a key mediator of tumor necrosis factor-alpha (TNF-alpha) signaling, in patients with rheumatoid arthritis (RA) before and during treatment with anti-TNF-alpha or methotrexate (MTX). We analyzed association of gene expression with disease activity, rheumatoid factor (RF), age, sex, disease duration, treatment modality, and clinical response.Sixty patients consented for RNA analysis at baseline and after 2 and 6 weeks of treatment. Disease activity was quantified using Disease Activity Score (DAS28) and C-reactive protein (CRP). Expression of 67 TNF-alpha-responsive, NF-kappaB-regulated genes was measured using Affymetrix arrays and RT-PCR.METHODSSixty patients consented for RNA analysis at baseline and after 2 and 6 weeks of treatment. Disease activity was quantified using Disease Activity Score (DAS28) and C-reactive protein (CRP). Expression of 67 TNF-alpha-responsive, NF-kappaB-regulated genes was measured using Affymetrix arrays and RT-PCR.Expression of 34 genes was associated with DAS28-CRP, notably S100A12/calgranulin C, IL7R, and aquaporin 3. No association was observed with age, sex, RF, or disease duration. Expression of 16 genes changed in a manner that differed significantly between treatment groups. Eleven were reduced in anti-TNF-alpha-treated patients relative to MTX, while 5 were increased. The majority of these observations were confirmed using RT-PCR. Gene expression was not associated significantly with change in disease activity.RESULTSExpression of 34 genes was associated with DAS28-CRP, notably S100A12/calgranulin C, IL7R, and aquaporin 3. No association was observed with age, sex, RF, or disease duration. Expression of 16 genes changed in a manner that differed significantly between treatment groups. Eleven were reduced in anti-TNF-alpha-treated patients relative to MTX, while 5 were increased. The majority of these observations were confirmed using RT-PCR. Gene expression was not associated significantly with change in disease activity.NF-kappaB-dependent gene expression in peripheral leukocytes is highly correlated with RA activity as measured by DAS28-CRP. Expression of many genes responds differentially to anti-TNF-alpha versus MTX, suggesting fundamentally different effects on the NF-kappaB pathway. This peripheral blood expression signature provides candidate markers that could lead to development of a simple, minimally invasive pharmacodynamic assay for RA treatments directed at the NF-kappaB pathway. Combination of gene expression data with clinical scores and serum markers may provide more sensitive and predictive measures of RA disease activity.CONCLUSIONNF-kappaB-dependent gene expression in peripheral leukocytes is highly correlated with RA activity as measured by DAS28-CRP. Expression of many genes responds differentially to anti-TNF-alpha versus MTX, suggesting fundamentally different effects on the NF-kappaB pathway. This peripheral blood expression signature provides candidate markers that could lead to development of a simple, minimally invasive pharmacodynamic assay for RA treatments directed at the NF-kappaB pathway. Combination of gene expression data with clinical scores and serum markers may provide more sensitive and predictive measures of RA disease activity. To evaluate peripheral blood expression of genes regulated by nuclear factor-kappaB (NF-kappaB), a key mediator of tumor necrosis factor-alpha (TNF-alpha) signaling, in patients with rheumatoid arthritis (RA) before and during treatment with anti-TNF-alpha or methotrexate (MTX). We analyzed association of gene expression with disease activity, rheumatoid factor (RF), age, sex, disease duration, treatment modality, and clinical response. Sixty patients consented for RNA analysis at baseline and after 2 and 6 weeks of treatment. Disease activity was quantified using Disease Activity Score (DAS28) and C-reactive protein (CRP). Expression of 67 TNF-alpha-responsive, NF-kappaB-regulated genes was measured using Affymetrix arrays and RT-PCR. Expression of 34 genes was associated with DAS28-CRP, notably S100A12/calgranulin C, IL7R, and aquaporin 3. No association was observed with age, sex, RF, or disease duration. Expression of 16 genes changed in a manner that differed significantly between treatment groups. Eleven were reduced in anti-TNF-alpha-treated patients relative to MTX, while 5 were increased. The majority of these observations were confirmed using RT-PCR. Gene expression was not associated significantly with change in disease activity. NF-kappaB-dependent gene expression in peripheral leukocytes is highly correlated with RA activity as measured by DAS28-CRP. Expression of many genes responds differentially to anti-TNF-alpha versus MTX, suggesting fundamentally different effects on the NF-kappaB pathway. This peripheral blood expression signature provides candidate markers that could lead to development of a simple, minimally invasive pharmacodynamic assay for RA treatments directed at the NF-kappaB pathway. Combination of gene expression data with clinical scores and serum markers may provide more sensitive and predictive measures of RA disease activity. |
| Author | Badola, Sunita Ginsburg, Geoffrey S Coblyn, Jonathan S Le, Tinh Roubenoff, Ronenn Shadick, Nancy A Narang, Jigna Parker, Alex Izmailova, Elena S Weinblatt, Michael E Maier, Agnes |
| Author_xml | – sequence: 1 givenname: Alex surname: Parker fullname: Parker, Alex organization: Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA – sequence: 2 givenname: Elena S surname: Izmailova fullname: Izmailova, Elena S – sequence: 3 givenname: Jigna surname: Narang fullname: Narang, Jigna – sequence: 4 givenname: Sunita surname: Badola fullname: Badola, Sunita – sequence: 5 givenname: Tinh surname: Le fullname: Le, Tinh – sequence: 6 givenname: Ronenn surname: Roubenoff fullname: Roubenoff, Ronenn – sequence: 7 givenname: Geoffrey S surname: Ginsburg fullname: Ginsburg, Geoffrey S – sequence: 8 givenname: Agnes surname: Maier fullname: Maier, Agnes – sequence: 9 givenname: Jonathan S surname: Coblyn fullname: Coblyn, Jonathan S – sequence: 10 givenname: Nancy A surname: Shadick fullname: Shadick, Nancy A – sequence: 11 givenname: Michael E surname: Weinblatt fullname: Weinblatt, Michael E |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17696278$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kc1O3TAQRrOg4revUM2qu0hJrmObJUJtqYRUFizYXc21J8StY4cZh3IfkzciLZfVSPMdnW-kOauOUk50VJ02m7avW909nFRnIr-bptVK2-PqpDX6UnfGnlavd8RhHokxwi7m7IFeZiaRkBPkAdLiIiHDgK5krv_gPOOuZnpcIhby8EiJBIIAimQX_u_-hjICj7RMWHLwgFxGDmWFfBBCIVhl4TmUPWDysLbNOfl_6TAQUyoBY9xDyWtcQl2WKTMkcpxldRwuwTiPCM_EsghMVMZcmF7W_ovq04BR6PNhnlf337_dX9_Ut79-_Ly-uq1H29vaO9sYc0nKON2b1irvdsYjoVOGLOkGnXO92bSdUs1GD1ZZNFq5vh985zrszquv79qZ89NCUrZTEEcxYqK8yFbbTjW92qzglwO47Cby25nDhLzffvygewOufYwY |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 17696278 |
| Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .GJ 0R~ 123 18M 1KJ 3O- 4.4 53G 5RE 6PF AAFWJ AAQQT AAWTL ABCQX ABJNI ACGFO ACGFS ADCBC AENEX AFFNX AI. ALMA_UNASSIGNED_HOLDINGS BR6 CGR CUY CVF EBS ECM EIF EJD EMOBN F5P H13 HZ~ J5H L7B MJL NPM O9- P0W P2P RHI SJN TJE VH1 W2D X7M XBR XDU XOL YQJ ZGI ZXE ZXP 7X8 |
| ID | FETCH-LOGICAL-h858-dc80779e47c657184dcb7daeac47e8e60accc5731244036f848a764c55fd2c2a2 |
| IEDL.DBID | 7X8 |
| ISSN | 0315-162X |
| IngestDate | Thu Jul 10 17:23:52 EDT 2025 Mon Jul 21 05:43:41 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-h858-dc80779e47c657184dcb7daeac47e8e60accc5731244036f848a764c55fd2c2a2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 17696278 |
| PQID | 68240543 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_68240543 pubmed_primary_17696278 |
| PublicationCentury | 2000 |
| PublicationDate | 2007-Sep 20070901 |
| PublicationDateYYYYMMDD | 2007-09-01 |
| PublicationDate_xml | – month: 09 year: 2007 text: 2007-Sep |
| PublicationDecade | 2000 |
| PublicationPlace | Canada |
| PublicationPlace_xml | – name: Canada |
| PublicationTitle | Journal of rheumatology |
| PublicationTitleAlternate | J Rheumatol |
| PublicationYear | 2007 |
| SSID | ssj0016468 |
| Score | 1.8354585 |
| Snippet | To evaluate peripheral blood expression of genes regulated by nuclear factor-kappaB (NF-kappaB), a key mediator of tumor necrosis factor-alpha (TNF-alpha)... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1817 |
| SubjectTerms | Adult Aged Antirheumatic Agents - pharmacology Arthritis, Rheumatoid - drug therapy Biomarkers Down-Regulation - drug effects Female Gene Expression Regulation - drug effects Humans Male Methotrexate - pharmacology Middle Aged NF-kappa B p50 Subunit - drug effects Receptors, Tumor Necrosis Factor - administration & dosage Severity of Illness Index Tumor Necrosis Factor-alpha - antagonists & inhibitors Up-Regulation - drug effects |
| Title | Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/17696278 https://www.proquest.com/docview/68240543 |
| Volume | 34 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9tAEF5RQIgLbSnlUWjnwHXVxN6XJSRUVSAuRDlwyC3al0nUYKdOguBn8o-YWTvqCXHoxQevH6ud2W9GO4-PsXPlQ2GUc1wFl3Ohy4K7zBY8j8oVZdGTuKUS2YQeDMxoVAw32MW6FobSKteYmIA61J7OyH8qg7ZHivxy_pcTZxTFVjsCjQ9sK0dHhnRaj_7FEJRIhXBEY8D7Khu97UMmW3L98f9m8YntdT4k_GqF_pltxGqf7dx2UfIv7GWIapXaBcwgJaZDfOryXSuoS6ioh7FtoOXa4X_sfG4db1pW-hjgnvAPpguwnezwHp3XQjOJK_Rw62kA1LhJ6ocEXYgHqEKCiCjAVgGalHobaLQlYEEgmc2eYVnj8HLKl6uHuoEqkpHGb3QzSYW_QIkiqwUkbutlE5_w_wfs7vrq7vcN76gb-MRIw4M3Pa2LKLRXEq2fCN7pYBHkhY4mqp713kudk3OBJrQ0wlithJeyDJnPbPaVbVZ1FY8YWISdMncxtzLis4URLkrrrQx9L_rCH7Mfa0mNcWdQuMNWsV4txmtZHbPDVtjjedvAY9zXijiHzMm7735ju-1hLiWVnbKtEjEhnrFt_4gL3HxPCofXwfD2FY407KU |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Peripheral+blood+expression+of+nuclear+factor-kappab-regulated+genes+is+associated+with+rheumatoid+arthritis+disease+activity+and+responds+differentially+to+anti-tumor+necrosis+factor-alpha+versus+methotrexate&rft.jtitle=Journal+of+rheumatology&rft.au=Parker%2C+Alex&rft.au=Izmailova%2C+Elena+S&rft.au=Narang%2C+Jigna&rft.au=Badola%2C+Sunita&rft.date=2007-09-01&rft.issn=0315-162X&rft.volume=34&rft.issue=9&rft.spage=1817&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0315-162X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0315-162X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0315-162X&client=summon |